Benefits of dietary sodium restriction in the management of chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 6, 2009, Pages 531-538

  Krikken, Jan A ^a   Laverman, Gozewijn U ^a   Navis, Gerjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic kidney disease; Dietary sodium intake; Renin Angiotensin Aldosterone system blockade

Indexed keywords

IRBESARTAN; LOSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ALBUMINURIA; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIET RESTRICTION; DISEASE ASSOCIATION; GLOMERULUS FILTRATION; HEART FAILURE; HUMAN; HYPERTENSION; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SODIUM INTAKE; SODIUM RESTRICTION; URINARY EXCRETION; CHRONIC DISEASE; DIET THERAPY; DRUG COMBINATION; GLOMERULUS FILTRATION RATE; KIDNEY DISEASE; MULTIMODALITY CANCER THERAPY; SALT INTAKE; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DIET, SODIUM-RESTRICTED; DIURETICS; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE, DIETARY; TREATMENT OUTCOME;

EID: 73349131138     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283312fc8     Document Type: Review

References (91)

1. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1-S290.
2. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensln- convertingenzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensln-Converting-Enzyme Inhibition in Progressive Renal insufficiency Study Group. N Engl J Med 1996; 334:939-945.
3. Estado RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapri on cardiovascular outcomes in patients with noninsulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-652.
4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860. (Pubitemid 34940824)
5. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 ; 345:870-878. (Pubitemid 34940826)
6. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431.
7. Parving HH, Persson F, Lewis JB, et al. Allskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433-2446.
8. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869. (Pubitemid 34940825)
9. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330:877-884.
10. Randomised placebo-controlled trial of effect of ramipri on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. The GISEN Group (Gruppo Italiano di Stud Epidemiologici in Nefrologia). Lancet 1997; 349:1857-1863.
11. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotaction in patients with nondiabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365:939-946. (Pubitemid 41071427)
12. De Nicola L, Minutolo R, Chiodin P, et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int 2006; 69:538-545. (Pubitemid 43164447)
13. Van Zuilen AD, Wetzels JF, Bots ML, Van Blankestijn RJ. MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. J Nephrol 2008; 21: 261-267.
14. Tuomilehto J, Jousilahti P, Rastenyte D, et al. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet 2001; 357: 848-851. (Pubitemid 32239370)
15. Verhave JC, Hillege HL, Burgerhof JG, et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 2004; 256: 324-330.
16. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 h urinary sodium and potassium excretion, Intersalt Cooperative Research Group. BMJ 1988; 297:319-328.
17. He FJ, MacGregor GA. Importance of salt in determining blood pressure in children: meta-analysis of controlled trials. Hypertension 2006; 48:861-869. (Pubitemid 44610998)
18. Schreuder MF, Bokenkamp A, van Wijk JA. Salt intake in children: increasing concerns? Hypertension 2007; 49:e10.
19. Tunstall-Pedoe H, Woodward M, Tavendale R, et al. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ 1997; 315:722-729. (Pubitemid 27405828)
20. Cohen HW, Hailpern SM, Fang J, Alderman MH. Sodium intake and mortality in the NHANES II follow-up study. Am J Med 2006; 119:275-314.
21. Leiba A, Vald A, Peleg E, et al. Does dietary recall adequately assess sodium, potassium, and calcium intake in hypertensive patients? Nutrition 2005; 21:462-466.
22. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334:885.
23. Kreutz R, Kovacevic L, Schulz A, et al. Effect of high NaCI diet on spontaneous hypertension in a genetic rat model with reduced nephron number. J Hypertens 2000; 18:777-782.
24. Dworkin LD, Benstein JA, Tolbert E, Feiner HD. Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease. J Am Soc Nephrol 1996; 7:437-442.
25. Visser FW, Boonstra AH, Titia Lely A, et al. Renal response to angiotensin II is blunted in sodium-sensitive normotensive men. Am J Hypertens 2008; 21:323-328. (Pubitemid 351323277)
26. Koomans HA, Roos JC, Boer P, et al. Salt handling in patients with chronic renal insufficiency. Miner Electrolyte Metab 1982; 7:134-145.
27. Weir MR, Dengel DR, Behrens MT, Goldberg AP. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995; 25:1339-1344.
28. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of Iosartan. J Am Soc Nephrol 2008; 19:999-1007.
29. Strojek K, Grzeszczak W, Lacka B, et al. Increased prevalence of salt sensitivity of blood pressure in IDDM with and without microalbuminuria. Diabetologia 1995; 38:1443-1448.
30. Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension 1991; 18: 67-71.
31. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002;346:913-923. (Pubitemid 34984641)
32. Konishi Y, Okada N, Okamura M, et al. Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy. Hypertension 2001; 38:81-85. (Pubitemid 34224775)
33. Bigazzi R, Bianchi S, Baldari D, et al. Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 1994; 23:195-199.
34. Swift PA, Markandu ND, Sagnella GA, et al. Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial. Hypertension 2005; 46:308-312.
35. Krikken JA, Lely AT, Bakker SJ, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007; 71:260-265. (Pubitemid 46160927)
36. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36:272-279.
37. Buter H, Hemmelder MH, Navls G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13:1682-1685. (Pubitemid 28306794)
38. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983; 23:647-655.
39. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51:793-797.
40. Bosma PJ, Kwakernaak AJ, van der Heide JJ, et al. Body mass index and glomerular hyperfiltration in renal transplant recipients: cross-sectional analysis and long-term impact. Am J Transplant 2007; 7:645-652.
41. Krikken JA, Bakker SJ, Navis GJ. Role of renal haemodynamics in the renal risks of overweight. Nephrol Dial Transplant 2009; 24:1 708-1711.
42. Visser FW, Krikken JA, Muntinga JH, et al. Rise in extracellular fluid volume during high sodium depends on BMI in healthy men. Obesity (Silver Spring) 2009 [Epub ahead of print].
43. Luik PT, Hoogenberg K, van der Kleij FG, et al. Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric type I diabetes mellitus. Diabetologia 2002; 45:535-541. (Pubitemid 34537287)
44. Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 2003; 14:530-537. (Pubitemid 36150878)
45. Navis G, de Jong PE, Donker AJ, et al. Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int 1987; 31:815-819. (Pubitemid 17025915)
46. Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 1996; 125:201-204. (Pubitemid 126449263)
47. Navis G, de Jong P, Donker AJ, et al. Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J Cardiovasc Pharmacol 1987; 9:743-748. (Pubitemid 17095578)
48. Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiprotelnuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16:474-481. (Pubitemid 41725144)
49. Wapstra FH, van Goor H, Navis G, et al. Antiprotelnuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci (Lond) 1996; 90:393-401. (Pubitemid 26149407)
50. Houlihan CA, Allen TJ, Baxter AL, et al. A low sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002; 25:663-671.
51. van de Wal RM, Gansevoort RT, van der Harst P, et al. Predictors of angiotensln-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension 2006; 48:870-876.
52. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with nondiabetic renal disease. Kidney Int Suppl 1994; 45:S174-S178.
53. Guida B, De Nicola L, Pecoraro P, et al. Abnormalities of bioimpedance measures in overweight and obese hemodialyzed patients, Int J Obes Relat Metab Disord 2001; 25:265-272. (Pubitemid 32158252)
54. Lufft V, Kliem V, Hamkens A, et al. Antiproteinuric efficacy of fosinopril after renal transplantation Is determined by the extent of vascular and tubulointerstitial damage. Clin Transplant 1998; 12:409-415. (Pubitemid 28446130)
55. Kramer AB, Laverman GD, van Goor H, Navis G. Inter-individual differences in antiproteinurlc response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage. J Pathol 2003; 201:160-167. (Pubitemid 37121215)
56. Kramer AB, Bos H, van Goor H, Navis GJ. Sodium intake modifies the negative prognostic value of renal damage prior to treatment with ACE inhibitors on proteinuria induced by adriamycin. Nephron Physiol 2006; 103:43-52.
57. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 2001; 12:2832-2837.
58. Hamming I, Navis G, Kocks MJ, van Goor H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol 2006; 209:129-139.
59. Vogt L, Kocks MJ, Laverman GD, Navis G. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and nondiabetic chronic kidney disease. Specific involvement of intra-renal angiotensln-converting enzyme activity in therapy resistance? Minerva Med 2004; 95:395-409.
60. van der Kleij FG, de Jong PE, Henning RH, et al. Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol 2002; 13:1025-1033.
61. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensinconverting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88:1L-20L
62. Largo R, Gomez-Garre D, Soto K, et al. Angiotensin-Converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 1999;33:732-739. (Pubitemid 29091657)
63. Rook M, Lely AT, Kramer AB, et al. Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage. Nephrol Dial Transplant 2005; 20:59-64. (Pubitemid 40207608)
64. Bos H, Laverman GD, Henning RH, et al. Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats. J Renin Angiotensin Aldosterone Syst 2003; 4:106-112. (Pubitemid 36790182)
65. Kocks MJ, Buikema H, Gschwend S, et al. High dietary sodium blunts affects of anglotensin-converting enzyme inhibition on vascular angiotensin I-to-angiotensin II conversion in rats. J Cardiovasc Pharmacol 2003; 42: 601-606. (Pubitemid 37305977)
66. Boddi M, Poggesi L, Coppo M, et al. Human vascular renin-angiotensin system and its functional changes in relation to different sodium intakes. Hypertension 1998; 31:836-842. (Pubitemid 28108584)
67. van der Kleij FG, Schmidt A, Navis GJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int Suppl 1997; 63:S23-S26. (Pubitemid 28020426)
68. Mizuirl S, Yoshikawa H, Tanegashima M, et al. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis 1998; 31:301-307. (Pubitemid 28106422)
69. Metzger R, Bohle RM, Pauls K, et al. Angiotensln-converting enzyme in nonneoplastic kidney diseases. Kidney Int 1999; 56:1442-1454. (Pubitemid 29451251)
70. Sanders PW. Effect of salt Intake on progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2006; 15:54-60. (Pubitemid 43755834)
71. Titze J, Ritz E. Salt and Its effect on blood pressure and target organ damage: new pieces in an old puzzle. J Nephrol 2009; 22:177-189.
72. Boonstra AH, Gschwend S, Kocks MJ, et al. Does a low-salt diet exert a protective effect on endothelial function in normal rats? J Lab Clin Med 2001; 138:200-205.
73. Ying WZ, Sanders PW. Dietary salt modulates renal production of transforming growth factor-beta in rats. Am J Physiol 1998; 274:F635-F641.
74. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 2007; 293:C509-C536.
75. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63:1791-1800.
76. Nagase M, Matsui H, Shibata S, et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticold receptor: role of oxidative stress. Hypertension 2007; 50:877-883. (Pubitemid 350287529)
77. Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for endstage renal disease. Ann intern Med 2006; 144:21-28. (Pubitemid 46780716)
78. Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17:1695-1702. (Pubitemid 43794672)
79. Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65:1870-1876.
80. Tozawa M, Iseki K, Iseki C, et al. Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62:956-962.
81. Rocchinl AP, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989; 321:580-585. (Pubitemid 19212870)
82. He J, Ogden LG, Vupputuri S, et al. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 1999; 282:2027-2034.
83. He J, Ogden LG, Bazzano LA, et al. Dietary sodium intake and incidence of congestive heart failure in overweight US men and women: first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Arch Intern Med 2002; 162:1619-1624. (Pubitemid 34765011)
84. Bosma PJ, van der Heide JJ, Oosterop EJ, et al. Body mass index is associated with altered renal hemodynamics in nonobese healthy subjects. Kidney Int 2004; 65:259-265.
85. Price DA, Lansang MC, Osei SY, et al. Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan. Diabet Med 2002; 19:858-861.
86. Damman K, van Deursen VM, Navis G, et al. Increased central venous pressure Is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53:582-588.
87. Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007; 28:166-171.
88. Dyer A, Elliott P, Chee D, Stamler J. Urinary biochemical markers of dietary intake in the INTERSALT study. Am J Clin Nutr 1997; 65:1246S-1253S.
89. World Action on Salt and Health (WASH) ; 2009.www.worldactiononsalt.com.
90. Machnik A, Neuhofer W, Jantsch J, et al. Macrophages regulate saltdependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 2009; 15:545-552.
91. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-S266.